{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:24:36Z","timestamp":1777929876760,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Palliative Medicine Reports"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>No standard treatment for cancer-related fatigue (CRF) for inpatients in a palliative care setting exists. The aim of this study was to validate the previous study-derived efficacy of dexamethasone 8\u2009mg for CRF among inpatients in a palliative care setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Inpatients with moderate fatigue (\u22654\/10) were enrolled in a multicenter phase II trial. Dexamethasone 8\u2009mg p.o. or 6.6\u2009mg i.v. was administered for seven days and 4\u2009mg p.o. or 3.3\u2009mg i.v. for seven consecutive days. The primary endpoint was a threshold average change of Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue subscale score of 3. The secondary endpoints were evaluated with the anorexia-cachexia subscale (ACS), and the Edmonton symptom assessment scale-revised Japanese version.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 32 patients were enrolled. On day 8, the mean change of FACIT-fatigue subscale from day 1 was 5.2 (95% confidence interval 0.8\u201310.0), in which the lower bound was above 0 but not above the prespecified threshold value of 3.0 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.72). Edmonton symptom assessment system (ESAS)-fatigue was significantly improved by day 3 (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.02), but not on day 8 or day 15. ACS, physical well-being, and ESAS-lack of appetite significantly improved by day 8 and day 15. Adverse events were tolerable.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study showed that dexamethasone 8\u2009mg failed to achieve the preset efficacy for CRF among inpatients in a palliative care setting. However, this treatment improved fatigue and would be an option for CRF.<\/jats:p>\n                    <jats:p>jRCT (jRCTs031180068).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/pmr.2021.0053","type":"journal-article","created":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T17:26:24Z","timestamp":1637169984000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Dexamethasone 8\u2009mg for Cancer-Related Fatigue in Inpatients with Advanced Cancer Undergoing Palliative Care: A Multicenter Phase II Trial"],"prefix":"10.1177","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-7279","authenticated-orcid":false,"given":"Tomofumi","family":"Miura","sequence":"first","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Okizaki","sequence":"additional","affiliation":[{"name":"Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Hasuo","sequence":"additional","affiliation":[{"name":"Department of Psychosomatic Medicine, Kansai Medical University, Hirakata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eriko","family":"Satomi","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8081-5979","authenticated-orcid":false,"given":"Keita","family":"Tagami","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kengo","family":"Imai","sequence":"additional","affiliation":[{"name":"Seirei Hospice, Seirei Mikatahara General Hospital, Hamamatsu, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironaga","family":"Satake","sequence":"additional","affiliation":[{"name":"Cancer Treatment Center, Kansai Medical University Hospital, Hirakata, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Ishiki","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Palliative Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,11,17]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"crossref","unstructured":"Rao A Cohen HJ: Symptom management in the elderly cancer patient: Fatigue pain and depression. J Natl Cancer Inst Monogr 2004;2004:150\u2013157.","DOI":"10.1093\/jncimonographs\/lgh031"},{"key":"e_1_3_6_3_2","doi-asserted-by":"crossref","unstructured":"Morita T Sakaguchi Y Hirai K et al.: Desire for death and requests to hasten death of Japanese terminally ill cancer patients receiving specialized inpatient palliative care. J Pain Symptom Manage 2004;27:44\u201352.","DOI":"10.1016\/j.jpainsymman.2003.05.001"},{"key":"e_1_3_6_4_2","doi-asserted-by":"crossref","unstructured":"Okuyama T Akechi T Kugaya A et al.: Development and validation of the cancer fatigue scale: A brief three-dimensional self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 2000;19:5\u201314.","DOI":"10.1016\/S0885-3924(99)00138-4"},{"key":"e_1_3_6_5_2","doi-asserted-by":"crossref","unstructured":"Mustian KM Alfano CM Heckler C et al.: Comparison of pharmaceutical psychological and exercise treatments for cancer-related fatigue: A meta-analysis. JAMA Oncol 2017;3:961\u2013968.","DOI":"10.1001\/jamaoncol.2016.6914"},{"key":"e_1_3_6_6_2","doi-asserted-by":"crossref","unstructured":"Yennurajalingam S Frisbee-Hume S Palmer JL et al.: Reduction of cancer-related fatigue with dexamethasone: A double-blind randomized placebo-controlled trial in patients with advanced cancer. J Clin Oncol 2013;31:3076\u20133082.","DOI":"10.1200\/JCO.2012.44.4661"},{"key":"e_1_3_6_7_2","doi-asserted-by":"crossref","unstructured":"Paulsen \u00d8 Klepstad P Rosland JH et al.: Efficacy of methylprednisolone on pain fatigue and appetite loss in patients with advanced cancer using opioids: A randomized placebo-controlled double-blind trial. J Clin Oncol 2014;32:3221\u20133228.","DOI":"10.1200\/JCO.2013.54.3926"},{"key":"e_1_3_6_8_2","doi-asserted-by":"crossref","unstructured":"Matsuo N Morita T Matsuda Y et al.: Predictor of responses to corticosteroids for cancer-related fatigue in advanced cancer patients: A multicenter prospective observational study. J Pain Symptom Manage 2016;52:64\u201372.","DOI":"10.1016\/j.jpainsymman.2016.01.015"},{"key":"e_1_3_6_9_2","doi-asserted-by":"crossref","unstructured":"Minton O Richardson A Sharpe M et al.: A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. J Natl Cancer Inst 2008;100:1155\u20131166.","DOI":"10.1093\/jnci\/djn250"},{"key":"e_1_3_6_10_2","doi-asserted-by":"crossref","unstructured":"Minton O Richardson A Sharpe M et al.: Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 2010:CD006704.","DOI":"10.1002\/14651858.CD006704.pub3"},{"key":"e_1_3_6_11_2","doi-asserted-by":"crossref","unstructured":"Temel JS Abernethy AP Currow DC et al.: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised double-blind phase 3 trials. Lancet Oncol 2016;17:519\u2013531.","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_3_6_12_2","doi-asserted-by":"crossref","unstructured":"Yokomichi N Morita T Nitto A et al.: Validation of the Japanese version of the edmonton symptom assessment system-revised. J Pain Symptom Manage 2015;50:718\u2013723.","DOI":"10.1016\/j.jpainsymman.2015.05.014"},{"key":"e_1_3_6_13_2","doi-asserted-by":"crossref","unstructured":"Hui D Park M Shamieh O et al.: Personalized symptom goals and response in patients with advanced cancer. Cancer 2016;122:1774\u20131781.","DOI":"10.1002\/cncr.29970"},{"key":"e_1_3_6_14_2","doi-asserted-by":"crossref","unstructured":"Tagami K Kawaguchi T Miura T et al.: The association between health-related quality of life and achievement of personalized symptom goal. Supportive Care in Cancer 2020;28:4737\u20134743.","DOI":"10.1007\/s00520-020-05316-0"},{"key":"e_1_3_6_15_2","doi-asserted-by":"crossref","unstructured":"Inouye SK Schlesinger MJ Lydon TJ: Delirium: A symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med 1999;106:565\u2013573.","DOI":"10.1016\/S0002-9343(99)00070-4"},{"key":"e_1_3_6_16_2","doi-asserted-by":"crossref","unstructured":"Miura T Matsumoto Y Kawaguchi T et al.: Low phase angle is correlated with worse general condition in patients with advanced cancer. Nutr Cancer 2019;71:83\u201388.","DOI":"10.1080\/01635581.2018.1557216"},{"key":"e_1_3_6_17_2","doi-asserted-by":"crossref","unstructured":"Evans DC Corkins MR Malone A et al.: The use of visceral proteins as nutrition markers: An ASPEN position paper. Nutr Clin Pract 2021;36:22\u201328.","DOI":"10.1002\/ncp.10588"},{"key":"e_1_3_6_18_2","doi-asserted-by":"crossref","unstructured":"Newton R Shah S Altonsy MO Gerber AN: Glucocorticoid and cytokine crosstalk: Feedback feedforward and co-regulatory interactions determine repression or resistance. J Biol Chem 2017;292:7163\u20137172.","DOI":"10.1074\/jbc.R117.777318"},{"key":"e_1_3_6_19_2","doi-asserted-by":"crossref","unstructured":"Barnes PJ: Mechanisms and resistance in glucocorticoid control of inflammation. J Steroid Biochem Mol Biol 2010;120:76\u201385.","DOI":"10.1016\/j.jsbmb.2010.02.018"},{"key":"e_1_3_6_20_2","doi-asserted-by":"crossref","unstructured":"Ronchetti S Migliorati G Bruscoli S Riccardi C: Defining the role of glucocorticoids in inflammation. Clin Sci 2018;132:1529\u20131543.","DOI":"10.1042\/CS20171505"},{"key":"e_1_3_6_21_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i36.6628"},{"key":"e_1_3_6_22_2","doi-asserted-by":"crossref","unstructured":"Schakman O Kalista S Barb\u00e9 C et al.: Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013;45:2163\u20132172.","DOI":"10.1016\/j.biocel.2013.05.036"}],"container-title":["Palliative Medicine Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/pmr.2021.0053","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2021.0053","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/pmr.2021.0053","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:56:19Z","timestamp":1777679779000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.1089\/pmr.2021.0053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/pmr.2021.0053"],"URL":"https:\/\/doi.org\/10.1089\/pmr.2021.0053","relation":{},"ISSN":["2689-2820","2689-2820"],"issn-type":[{"value":"2689-2820","type":"print"},{"value":"2689-2820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]},"article-number":"pmr.2021.0053"}}